The present and future of cervical cancer screening programmes in Europe

Current Pharmaceutical Design

Volumn 19, Issue 8, 2013, Pages 1490-1497

  Rossi, Paolo Giorgi ^a   Ronco, Guglielmo ^b  

^a PATHOLOGY UNIT   (Italy)

^b Cancer Epidemiology Unit   (Italy)

Author keywords

Cervical cancer; Colposcopy; Cytology; HPV; HPV testing; Pap Test; Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLPOSCOPY; CYTOLOGY; EUROPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84876708898     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319080016     Document Type: Article

References (50)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-9.
2. IARC Handbooks of Cancer Prevention Vol. 10 Cervix Cancer Screening. IARC, Lion, 2005
3. Bouvard VA, Baan RA, Straif KA, et al. On behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Special report: policy. A review of human carcinogens-part B: biological agents. Lancet Oncol 2009; 10: 321-322.
4. WHO/ICO Information Centre on HPV and Cervical Cancer. http: //www.who.int/hpvcentre/en/
5. IARC. Globocan 2008. Cancer fact sheet: Cervical Cancer Incidence and Mortality Worldwide in 2008. Avilable at (last access 6/4/2012): http: //globocan.iarc.fr/factsheets/cancers/cervix.asp
6. Castellsagué X, de Sanjosé S, Aguado T, et al. HPV and Cervical Cancer in the World 2007 Report. Vaccine 2007; 25(suppl 3): 1-241.
7. de Sanjosé S, Diaz M, Castellsagué X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7(7): 453-9.
8. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer. Int J Cancer 2012 Feb 9. doi: 10.1002/ijc.27485.
9. Franceschi S, Herrero R, Clifford GM, et al. Variations in the agespecific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119(11): 2677-84.
10. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128(4): 927-35.
11. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102(19): 1478-88.
12. Dillner J, Rebolj M, Birembaut P, et al. Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
13. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97(14): 1072-9.
14. Anttila A, von Karsa L, Aasmaa A, et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 2009; 45: 2649-58.
15. Anttila A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer Screening Programmes in the European Union within the European Network for Information on Cancer (EUNICE). Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2685-708.
16. WHO World Health Survey. http: //www.who.int/ healthinfo/survey/en (7 January 2009, date last accessed).
17. Palència L, Espelt A, Rodríguez-Sanz M, et al. Socio-economic inequalities in breast and cervical cancer screening practices in Europe: influence of the type of screening program. Int J Epidemiol 2010; 39(3): 757-65.
18. Debra L. Blackwell, Michael E. Martinez, Jane F. Gentleman, Women's Compliance with Public Health Guidelines for Mammograms and Pap tests in Canada and the United States: An Analysis of Data from the Joint Canada/United States Survey of Health, Women's Health Issues 2008; 18: 85-99
19. Council Recommendation 2 December 2003 on cancer screening 2003/878/EC
20. Arbyn M, Anttila A, Jordan J, et al. editors; European Commission. In. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd edition. Luxembourg: Office for Official Publications of the European Communities 2008; p. 1-291
21. U.S. Preventive Services Task Force. Screening for Cervical Cancer 2003
22. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D 2006 American Society for Colposcopy and Cervical Pathology-sponsored Consensus Conference 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197(4): 346-55.
23. Saslow D, Solomon D, Lawson HW, et al. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012; 137(4): 516-42.
24. Moyer VA; on behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012 Mar 14 [Epub ahead of print].
25. Cuzick J, Clavel C, Petry CH, et al. Overview of the European and north American studies on HPV testing in primary cervical screening. Int J Cancer 2006; 119: 1095-101.
26. Sawaya GF. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone". Arch Intern Med 2010; 170(11): 985-6.
27. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolau tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
28. Naucler P, Ryd W, Tornberg S, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer inst 2009; 101: 88-99.
29. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papilllomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007 24; 370: 1764-72.
30. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009; 10: 672-82.
31. Ronco G, Segnan N, Giorgi-Rossi P, et al. Human Papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-74.
32. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-55.
33. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomised controlled trial comparing human papillomavirus testing alone with conventional cytology as a primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
34. Leinonen M, Nieminen P, Kotaniemi Talonen L, et al. Age specific Evaluation of primary human papillomavirus screening vs. conven tional cytology in a randomised setting. J Nat Cancer Inst 2009; 101: 1612-32.
35. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
36. Ronco G, Giorgi-Rossi P, Carozzi F, et al. New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11(3): 249-57.
37. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012; 13(1): 78-88.
38. Franceschi S, Denny L, Irwin KL, et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011; 128(12): 2765-74.
39. Ronco G, Meijer JLMC. HPV Screening: Available Data and Recommendations for Clinical Practice. Cur Cancer Ther Rev 2010; 6: 104-109.
40. Ronco G, Biggeri A, Confortini M, et al. Eds. HTA Report. Use of the DNA human papillomavirus (hpv) as primary screening test for cervical precancer lesions. Epidemiol Prev 2012 (Submitted).
41. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124(3): 516-20.
42. Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 2007; 356: 1915-27.
43. Paavonen J, Jenkins D, Bosch FX, et al. HPV PATRICIA study group: Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind randomised controlled trial. Lancet 2007; 369(9580): 2161-70.
44. King LA, Levy-Bruhl D, O'Flanagan D, et al. VENICE countryspecific gate keepers and contact points: Introduction of human papillomavirus into national immunisation schedules in Europe: results of the VENICE 2007 survey. Euro Surveill 2008; 13(33): pii: 18954.
45. Bosch FX, Castellsagué X, de Sanjosé S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008, 98: 15-21.
46. Kiviat NB, Hawes SE, Feng Q. Screening for cervical cancer in the era of the HPV vaccine-the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst 2008; 100: 290-1.
47. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007, 370: 890-907.
48. Dalla Palma P, Giorgi Rossi P, Collina G, et al. the NTCC Pathology Group: The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histological lesions found in the NTCC trial. Am J Clin Pathol 2008; 129: 75-80.
49. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of typespecific HPV testing in clinical practice. J Natl Cancer Inst 2005, 97: 1072-9.
50. Giorgi Rossi P, Ronco G. HPV types in early-onset cervical cancer. Lancet Oncol 2011; 12(2): 117.